top of page

Development of disruptive treatment method
through therapeutic aerosols

Based in Germany, the company develops medical devices and drug formulations for the treatment of peritoneal cancer and has received several awards worldwide. Furthermore, the team of experts offers contract research for clinics and pharmaceutical companies.

  • First closing €1M for certification and approval

  • Second closing €3M for phase 1 and 2 clinical trials

  • Third Closing €6M for Phase 3 pivotal study and regulatory approval in Europe and the US

bottom of page